← Back to Search

Contrast-Enhanced Imaging for Liver Cancer (ACRIN6690 Trial)

N/A
Waitlist Available
Led By Christoph Wald, MD, PhD
Research Sponsored by American College of Radiology Imaging Network
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within 90 days before transplantation
Awards & highlights

ACRIN6690 Trial Summary

This trial is looking at how well contrast-enhanced CT and MRI scans can detect and stage liver cancer in patients with chronic liver disease.

Eligible Conditions
  • Liver Cancer

ACRIN6690 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~within 90 days before transplantation
This trial's timeline: 3 weeks for screening, Varies for treatment, and within 90 days before transplantation for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Sensitivity of contrast-enhanced CT scan vs contrast-enhanced MRI for diagnosing hepatocellular carcinoma (HCC)
Secondary outcome measures
Accuracy of imaging-based diagnosis and staging of HCC in clinical practice using the new OPTN liver-imaging criteria compared with the reference standard of pathologic diagnosis and staging at the time of explantation
Diagnostic value of sensitivity and PPV when patients are stratified by AFP level (elevated vs normal)
Lesion-level sensitivity and PPV of contrast CT scan vs contrast MRI
+2 more

ACRIN6690 Trial Design

1Treatment groups
Experimental Treatment
Group I: Waitlisted with HCC-Exception PointsExperimental Treatment3 Interventions
Participants undergo CT and MRI every 90 days for the trial with iodinated contrast dye and motexafin gadolinium, during liver transplant wait listing. Possible Eovist-enhanced MRI substudy participation
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Motexafin gadolinium
Not yet FDA approved

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,658 Previous Clinical Trials
40,924,049 Total Patients Enrolled
103 Trials studying Liver Cancer
26,228 Patients Enrolled for Liver Cancer
American College of Radiology Imaging NetworkLead Sponsor
39 Previous Clinical Trials
466,435 Total Patients Enrolled
1 Trials studying Liver Cancer
51 Patients Enrolled for Liver Cancer
Christoph Wald, MD, PhDPrincipal InvestigatorLahey Clinic Medical Center - Burlington

Media Library

iodinated contrast dye Clinical Trial Eligibility Overview. Trial Name: NCT01082224 — N/A
Liver Cancer Research Study Groups: Waitlisted with HCC-Exception Points
Liver Cancer Clinical Trial 2023: iodinated contrast dye Highlights & Side Effects. Trial Name: NCT01082224 — N/A
iodinated contrast dye 2023 Treatment Timeline for Medical Study. Trial Name: NCT01082224 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
HepatologyJournal
LI‐RADS (liver Imaging Reporting and Data System): Summary, Discussion, and Consensus of the LI‐RADS Management Working Group and Future Directions
Mitchell, Donald G., Jordi Bruix, Morris Sherman, and Claude B. Sirlin. 2014. “LI‐RADS (liver Imaging Reporting and Data System): Summary, Discussion, and Consensus of the LI‐RADS Management Working Group and Future Directions”. Hepatology. Wiley. doi:10.1002/hep.27304.
clinicaltrials.govStudy
Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy
2010. "Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01082224.
All > Liver Fibrosis > Liver Cancer
~31 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top